Journal of Biological Chemistry
Volume 295, Issue 39, 25 September 2020, Pages 13410-13418
Journal home page for Journal of Biological Chemistry

Accelerated Communications
Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite

https://doi.org/10.1074/jbc.AC120.014993Get rights and content
Under a Creative Commons license
open access

An important context in which metabolism influences tumorigenesis is the genetic cancer syndrome hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a disease in which mutation of the tricarboxylic acid cycle enzyme fumarate hydratase (FH) causes hyperaccumulation of fumarate. This electrophilic oncometabolite can alter gene activity at the level of transcription, via reversible inhibition of epigenetic dioxygenases, as well as posttranslationally, via covalent modification of cysteine residues. To better understand the potential for metabolites to influence posttranslational modifications important to tumorigenesis and cancer cell growth, here we report a chemoproteomic analysis of a kidney-derived HLRCC cell line. Using a general reactivity probe, we generated a data set of proteomic cysteine residues sensitive to the reduction in fumarate levels caused by genetic reintroduction of active FH into HLRCC cell lines. This revealed a broad up-regulation of cysteine reactivity upon FH rescue, which evidence suggests is caused by an approximately equal proportion of transcriptional and posttranslational modification–mediated regulation. Gene ontology analysis highlighted several new targets and pathways potentially modulated by FH mutation. Comparison of the new data set with prior studies highlights considerable heterogeneity in the adaptive response of cysteine-containing proteins in different models of HLRCC. This is consistent with emerging studies indicating the existence of cell- and tissue-specific cysteine-omes, further emphasizing the need for characterization of diverse models. Our analysis provides a resource for understanding the proteomic adaptation to fumarate accumulation and a foundation for future efforts to exploit this knowledge for cancer therapy.

chemical biology
metabolism
inborn error of metabolism
posttranslational modification (PTM)
proteomics
redox signaling
TCA cycle
mitochondria
tricarboxylic acid cycle (TCA cycle) (Krebs cycle)

Cited by (0)

This article contains supporting information.

Author contributions—M. P., D. W. B., S. E. B., E. W., and J. L. M. conceptualization; M. P., D. W. B., E. W., W. M. L., and J. L. M. data curation; M. P., D. W. B., D. R. C., E. W., W. M. L., and J. L. M. formal analysis; M. P., D. W. B., S. E. B., E. W., W. M. L., and J. L. M. investigation; M. P., D. W. B., S. E. B., D. R. C., B. S. A., Y. Y., E. W., W. M. L., and J. L. M. methodology; M. P., D. W. B., and J. L. M. writing-original draft; M. P., D. W. B., D. R. C., E. W., W. M. L., and J. L. M. writing-review and editing.

Funding and additional information—This work was supported by the Intramural Research Program of the NCI, National Institutes of Health, Center for Cancer Research (ZIA BC011488 and ZIA BC011038) and the CCR FLEX Program. Support for E. W. was provided by National Institutes of Health Grants 1R01GM117004 and 1R01GM118431-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are:

    HLRCC

    hereditary leiomyomatosis and renal cell carcinoma

    TCA

    tricarboxylic acid

    FH

    fumarate hydratase

    IA-alkyne

    iodoacetamide alkyne

    ReDiMe

    reductive dimethyl

    AMPK

    5'-AMP-activated protein kinase

    MHC

    major histocompatibility complex

    SICyLIA

    stable isotope cysteine labeling with iodoacetamide.